Effectiveness of platelet rich plasma in comparison with Triamcinolone Hexacetonide in improving pain and function in patients with de Quervains tenosynovitis: A Randomised controlled trial - Nil

开始日期2024-08-20

申办/合作机构

Regional Institute of Medical Sciences

CTRI/2024/06/069688

/ Not yet recruiting临床4期

A Prospective, Multicenter, Open-label, Post-Marketing Observational Study to Evaluate the Effectiveness and Safety of Triamcinolone Hexacetonide Intra-Articular Injection in Adhesive Capsulitis of the Shoulder (Frozen Shoulder) - NIL

开始日期2024-07-09

申办/合作机构

Abbott India Ltd.

NCT06308887

/ Completed临床4期IIT

Comparison of the Effectiveness of Ultrasound-Guided Perimeniscal Steroid and Dextrose Injections in Knee Osteoarthritis

Introduction: The primary goal of treating knee osteoarthritis is to reduce pain and improve the patient's quality of life. Medial meniscal extrusion is a condition that is linked to pain and disability in knee osteoarthritis and can be identified through ultrasound. For patients with medial meniscal extrusion, perimeniscal corticosteroid injection has been shown to be a helpful addition to primary treatment for moderate to severe pain relief. Dextrose prolotherapy has also been found to provide periarticular benefits for knee osteoarthritis. This study aims to compare the effectiveness of ultrasound-guided perimeniscal corticosteroid and perimeniscal dextrose injections in patients with osteoarthritis, medial knee pain, and medial meniscal extrusion.
Method: Patients with medial knee pain and meniscal extrusion were randomly divided into two groups using the double-block randomization method. Group 1 included 15 patients who were administered an ultrasound-guided perimeniscal steroid injection, while Group 2 included 16 patients who were administered an ultrasound-guided perimeniscal dextrose injection. The patients' pain levels were evaluated using the Visual Analog Pain Scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) before and one week, one month, and three months after the injection.

开始日期2023-10-02

申办/合作机构

Kastamonu University

100 项与己曲安奈德相关的临床结果

登录后查看更多信息

100 项与己曲安奈德相关的转化医学

登录后查看更多信息

100 项与己曲安奈德相关的专利（医药）

登录后查看更多信息

372

项与己曲安奈德相关的文献（医药）

2025-02-01·Journal of ISAKOS

Intra-articular injection of a cross-linked hyaluronic acid combined with triamcinolone hexacetonide improves pain at six months in patients with mild to moderate hip osteoarthritis: A prospective observational study

Article

作者: Rabinovich, Alexander ; Maida, Eugene ; Duong, Andrew ; de SA, Darren ; Kapuvari, Stephen ; Dessouki, Shariff ; Simunovic, Nicole ; Sim, Yan ; Hitchon, Maggie ; Ayeni, Olufemi R. ; Bourgeault-Gagnon, Yoan ; Williams, Ryan ; Lautenbach, Justin ; Heels-Ansdell, Diane ; Dalziel, Katie

OBJECTIVESJoint-preserving interventions, such as intra-articular viscosupplementation injections, are evolving and requiring efficacy and safety evaluations through an evidence-based approach. The objective of this study was to assess the use of a hyaluronic acid and corticosteroid-based injection (Cingal™; Anika Therapeutics, Bedford, MA, USA) in improving pain and functional outcomes for patients aged between 40 and 65 with mild to moderate hip osteoarthritis (OA) six months post-injection.METHODSThis prospective observational study included 100 patients receiving a single ultrasound-guided intra-articular injection of Cingal™. Eligible patients seen in participating orthopaedic, physiatry and sports medicine clinics were evaluated at baseline, one-month, and six-month follow-up. The primary outcome was patient-reported hip pain (Visual Analogue Scale, VAS) at six months post-injection. Secondary outcomes included hip function (Hip Disability and Osteoarthritis Outcome Score, HOOS), quality of life (Short-Form 12, SF-12), pain medication use, range of motion (ROM), physical activity (activity tracker), and adverse events.RESULTSNinety-six patients received the injection; 91 had complete data for primary outcome analysis. Statistically significant improvements were observed in VAS (p < 0.001), HOOS (p < 0.001), and SF-12 scores (Physical Component Summary, p = 0.005; Mental Component Summary, p = 0.022) from baseline to six months post-injection. Pain medication use decreased from 50.0% to 34.0% (p = 0.035). No statistically significant change was observed in ROM or activity level. Adverse events were reported in 9.5% of patients: five (5.3%) experienced hip pain for less than seven days, one for more than seven days but less than one month, and three (3.2%) underwent hip arthroplasty.CONCLUSIONPatients receiving an ultrasound-guided Cingal™ injection for hip OA reported statistically significantly reduced hip pain, improved function and quality of life, and reduced pain medication use at six months. The most common adverse event was transient hip pain.LEVEL OF EVIDENCEProspective observational study, Level III.

2024-11-16·Postgraduate Medicine

Juvenile idiopathic arthritis management: insights into the utilization of intra-articular corticosteroid injections

Article

作者: Yildirim, Deniz Gezgin ; Küçükali, Batuhan ; Belder, Nuran ; Sunar Yayla, Emine Nur ; Kutlar, Merve ; Bakkaloğlu, Sevcan A. ; Esmeray Şenol, Pelin ; Yıldız, Çisem ; Karaçayır, Nihal

BACKGROUNDJuvenile idiopathic arthritis (JIA) is a common chronic rheumatic disease in children, requiring careful management to reduce both short- and long-term morbidity. In this study, our objective was to assess the clinical features of patients diagnosed with JIA who received intra-articular corticosteroid injections (IACI).METHODSIn this retrospective study, we evaluated the clinical and laboratory characteristics of 225 JIA patients monitored from January 2012 to October 2023 at a tertiary care center. We focused on patients who underwent intra-articular corticosteroid injections (IACI) as part of their treatment. Triamcinolone hexacetonide (TH) was used due to its demonstrated safety and efficacy.RESULTSOur analysis revealed that IACI, particularly utilizing TH, was a widely employed and effective adjunct therapy, contributing to rapid symptom relief and local disease control. Patients receiving IACI exhibited earlier symptom onset, younger age at diagnosis, longer follow-up durations, and higher cumulative treatment burden (p < 0.001, p < 0.001, p < 0.01, p < 0.001 respectively). Despite inconclusive acute-phase reactants, a higher frequency of ANA positivity and elevated initial lymphocyte counts were associated with increased IACI use (p < 0.001, p < 0.001 respectively). Importantly, on a joint basis, a high percentage of arthritis remission following IACI underscores its efficacy and favorable safety profile.CONCLUSIONSNotably, the high percentage of arthritis remission achieved with intra-articular corticosteroid injections (IACI) on a joint-specific basis highlights its efficacy and favorable safety profile. A lymphocyte count exceeding 5000/mm³ at the time of diagnosis may serve as an early indicator for considering intra-articular steroid administration. These findings emphasize the need for nuanced and individualized treatment strategies in JIA management to optimize outcomes for affected children.

2024-10-01·Orthopaedics & Traumatology: Surgery & Research

Survivorship and outcomes of intra- and perimeniscal corticosteroids injections with structured physiotherapy for degenerative medial meniscus tears

Article

作者: Guenoun, Daphne ; Cavaignac, Etienne ; Mabrouk, Ahmed ; Onishi, Shintaro ; Jacquet, Christophe ; Ollivier, Matthieu

BACKGROUNDDegenerative medial meniscus tears are a common pathology in the general population. Recent randomized trials demonstrated non-superiority of arthroscopic partial meniscectomy over conservative management. However, there is a paucity of information regarding the outcomes of combined conservative treatments.HYPOTHESISIt was hypothesized that combined intra- and perimeniscal corticosteroid injections with structured physiotherapy, for degenerative medial meniscus tears, would result in high surgery-free and second injection-free survivorship.METHODSA retrospective review of 671 patients with symptomatic degenerative medial meniscus tears, who received intra- and perimeniscal corticosteroids injection combined with structured physiotherapy, was conducted. An ultrasound-guided injection of Triamcinolone Hexacetonide 20 mg/ml comprised; 1.5 ml intra-meniscal,1.5 ml in the meniscal wall, and 2 ml in the peri-meniscal space, was performed. Surgery free- and a second injection free-survivorship were analysed. Western Ontario and Macmaster University scores (WOMAC), Tegner activity scores, patient satisfaction, return-to-work status and average time to return to work were recorded.RESULTSA total of 481 patients who met the inclusion criteria were included. The mean age was 51.1 ± 7.9 years. At five years post-procedure, surgery-free, and second injection-free survivorship of the ipsilateral knee was 83%, and 52%, respectively. A multivariate analysis adjusting survival on parametric risk factors identified that only effusion before steroid injection was an independent risk factor of treatment failure. At a mean follow-up of 4 ± 2 years, there was an improvement in WOMAC scores by 5.2 ± 4.9 for pain, by 2 ± 2 for stiffness, by 7.3 ± 7.4 for function, and by 12.4 ± 12.7 for the global scores. Additionally, there was significant improvement in the Tegner activity scores (All p < 0.001). Knee effusion and advanced osteoarthritis (Kellgren-Lawrence > III) were significantly associated with poorer outcomes; p < 0.003 and p < 0.0004, respectively.CONCLUSIONA combination of intra- and perimeniscal corticosteroid injections and structured physiotherapy for degenerative medial meniscus tears, results in high surgery-free (83%) and second injection-free (52%) survivorship, as well as, effective clinical outcomes and satisfaction at 5 years.LEVEL OF EVIDENCEIV; Retrospective Case Series.

项与己曲安奈德相关的新闻（医药）

2021-06-09

·BioSpace

Medexus Announces Availability of Triamcinolone Hexacetonide in the United States

TORONTO and CHICAGO and MONTREAL, June 09, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it is initiating immediate availability of Triamcinolone Hexacetonide Injectable Suspension, USP (20 mg/ml) (TH) in the United States via the U.S. Food and Drug Administration’s (FDA) CDER Drug Shortage program. More information about the FDA’s Drug Shortage program is available at: FDA Drug Shortages. TH is indicated for intra-articular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases, including: rheumatoid arthritis, juvenile idiopathic arthritis (JIA), osteoarthritis and post-traumatic arthritis, synovitis, tendinitis, bursitis and epicondylitis. To address the ongoing shortage of TH in the United States, Medexus is coordinating with Ethypharm, its licensing partner, to generate the data needed to support an Abbreviated New Drug Application (ANDA) filing in an expedited timeframe. About Medexus Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action. For more information, please contact: Ken d’Entremont, Chief Executive Officer Medexus Pharmaceuticals Inc. Tel.: 905-676-0003 E-mail: ken.dentremont@medexus.com Roland Boivin, Chief Financial Officer Medexus Pharmaceuticals Inc. Tel.: 514-344-8765 E-mail: roland.boivin@medexus.com Investor Relations (U.S.): Crescendo Communications, LLC Tel: +1-212-671-1020 Email: mdp@crescendo-ir.com Investor Relations (Canada): Tina Byers Adelaide Capital Tel: 905-330-3275 E-mail: tina@adcap.ca Forward looking and other cautionary statements Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). The words “anticipates”, “believes”, “expects”, “will”, “plans” and similar expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Specific forward-looking statements contained in this news release include, but are not limited to, statements with respect to the immediate availability of TH in the United States and the Company’s ability to generate the data needed to support an ANDA filing in an expedited timeframe. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Material risk factors include those set out in the Company’s materials filed with the Canadian securities regulatory authorities from time to time, including the Company’s most recent annual information form and management’s discussion and analysis. Given these risks, undue reliance should not be placed on these forward-looking statements, which apply only as of the date hereof. Other than as specifically required by law, the Company undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Best in Class

2020-01-07

·SYNAPSE

Ardian sells Riemser to international pharmaceutical company Esteve

Ardian, a world-leading private investment house, has come to an agreement to sell all the shares of the German pharmaceutical company RIEMSER to ESTEVE, an international pharmaceutical company headquartered in Barcelona. Financial details of the transaction will not be disclosed. The closing of the transaction is subject to antitrust approval and is expected in the first quarter of 2020. RIEMSER is a provider of specialty pharmaceuticals in human medicine headquartered in Greifswald and Berlin. The Company has subsidiaries in Great Britain, France and Spain, and an international distribution network across more than 50 countries. With the acquisition of RIEMSER, ESTEVE broadens its access to the fast-growing hospital market, in which RIEMSER is particularly successful. Today, RIEMSER generates about 80 percent of its sales with products for clinical application. Numerous RIEMSER drugs are considered ‘gold standard’. Ardian acquired RIEMSER in 2012 and, together with the management team, successfully refocused the company on its core business of specialty pharmaceuticals, which it acquires, licenses, markets and distributes. Today, the company’s product portfolio comprises prescription drugs for the treatment of serious diseases in oncology, neurology, infectiology, as well as niche indications in cardiovascular medicine, dermatology, rheumatology and infectiology. RIEMSER has divested from areas which are not part of its core business, such as the dental and veterinary business and the medical devices business. The proceeds were invested in the licensing and acquisition of products, the acquisition of companies in the specialty pharmaceuticals sector and the expansion of indications for existing products: RIEMSER acquired Keocyt in France in 2014 and Intrapharm, based in England, in 2015. In 2016, the acquisition of the CNS division of Dolorgiet followed, whose products expanded the portfolio by the therapeutic area of neurology. In 2019, RIEMSER bought the Spanish distribution service provider Zaltanpharma, which has since been renamed RIEMSER Iberia. In the area of drug approval and in--licensing, RIEMSER, among others introduced the active ingredient triamcinolone hexacetonide in Canada and concluded an agreement with the Japanese pharmaceutical company Eisai on the exclusive development and marketing rights for Prialt in Europe in 2018; in 2019 Keocyt received a new EU approval for Zanosar in eleven European countries. Christof Naményi, Managing Director in the German Ardian Buyout team, said: "Ardian has extensive experience as an investor in the European healthcare, life sciences and pharmaceutical markets. We are pleased that we have been able to successfully leverage our expertise and network with RIEMSER, supporting the company’s acquisition strategy, corporate and organisational development, and executive recruitment. We would like to thank Konstantin von Alvensleben, his management team and all RIEMSER employees for the excellent cooperation and wish them all the best for the future.” Konstantin von Alvensleben, CEO of RIEMSER, added: "When I joined RIEMSER in 2015, Ardian had already set the course for the further development of the company. I am pleased that since then we have been able to accelerate this process and together reached further milestones in the growth and internationalisation of the business. Ardian’s support was invaluable in achieving this. We are very proud that with Esteve, a strong family-owned pharma company with a long tradition, has chosen to acquire Riemser and we are looking forward to entering the next stage of our development. Being part of a much larger Group will support our joint growth. "

上市批准并购引进/卖出

100 项与己曲安奈德相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00985	己曲安奈德	R01AD11 H02AB08 S01BA05 A01AC01 D07AB09 D07XB02 R03BA06 C05AA12	DBSALT000861

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
类风湿关节炎	加拿大	Medexus, Inc.	2017-12-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ACR2020	N/A	幼年特发性关节炎一线	102	Triamcinolone hexacetonide	製顧鏇鹽醖衊淵鏇衊壓(膚艱觸鏇艱獵築選壓繭) = 製觸鬱鑰夢糧顧積淵製衊構鏇糧鑰糧繭艱製憲 (鬱壓壓齋壓鏇醖遞獵鬱 ) 更多	积极	2020-11-07
ACR2020	N/A	幼年特发性关节炎一线	102	Triamcinolone acetonide	製顧鏇鹽醖衊淵鏇衊壓(膚艱觸鏇艱獵築選壓繭) = 夢淵鬱網窪淵觸鹹網構衊構鏇糧鑰糧繭艱製憲 (鬱壓壓齋壓鏇醖遞獵鬱 ) 更多	积极	2020-11-07
NCT01770912 (CTgov)	临床2期	疼痛	24	Lactated Ringers (Lactated Ringers)	醖齋構獵網衊衊窪鏇繭(鹽餘憲壓艱餘網糧鑰蓋) = 糧簾糧壓膚蓋壓淵簾憲鹹鹽鬱淵築襯觸選鏇鹽 (選遞鑰鑰醖網簾選膚遞, 衊鹽憲鹽築艱範衊憲構 ~ 憲齋醖網鏇餘遞鏇憲襯) 更多	-	2020-10-08
NCT01770912 (CTgov)	临床2期	疼痛	24	Triamcinolone hexacetonide (Triamcinolone Acetonide)	醖齋構獵網衊衊窪鏇繭(鹽餘憲壓艱餘網糧鑰蓋) = 糧願願網艱廠鏇衊積醖鹹鹽鬱淵築襯觸選鏇鹽 (選遞鑰鑰醖網簾選膚遞, 糧網窪築製構獵餘齋夢 ~ 願獵鬱遞積蓋鹽願艱獵) 更多	-	2020-10-08
EULAR2018	N/A	膝关节滑膜炎	159	20 mg triamcinolone hexacetonide	(繭齋鹹餘壓蓋糧顧艱獵) = 簾糧鹹憲襯選顧蓋壓觸膚願膚觸鬱襯蓋遞憲糧 (繭糧鏇壓鹽簾艱積蓋憲 )	-	2018-06-13
EULAR2018	N/A	膝关节滑膜炎	159	40 mg triamcinolone hexacetonide	(繭齋鹹餘壓蓋糧顧艱獵) = 艱鑰構鏇鏇獵積顧鏇餘膚願膚觸鬱襯蓋遞憲糧 (繭糧鏇壓鹽簾艱積蓋憲 )	-	2018-06-13
EULAR2014	N/A	风湿性疾病	-	Triamcinolone hexacetonide intra-articular injection	製鬱顧艱築積鹹願鬱憲(憲範顧蓋鹹製簾繭構膚) = 憲蓋衊糧觸鹹鹽積夢願獵願遞憲鹹衊艱觸鹹鑰 (夢憲遞膚憲齋積選顧壓 )	-	2014-06-11
EULAR2012	N/A	关节炎	27	Triamcinolone hexacetonide	齋鹹觸鏇鹽鑰鏇糧齋觸(夢製憲遞憲廠夢襯膚廠) = 淵願齋繭壓鑰衊簾糧齋淵窪觸衊蓋遞餘願鑰餘 (齋蓋憲夢鑰築獵構構鏇 ) 更多	积极	2012-06-06
EULAR2010	N/A	关节炎	15	Triamcinolone hexacetonide	夢積觸窪蓋齋齋繭選網(餘願網艱壓鏇鏇築獵範) = 鬱艱憲範鹽淵築願觸獵襯醖選築齋淵淵鹽廠衊 (鹹艱網繭糧膚網蓋網鬱, 14.29) 更多	-	2010-06-16
EULAR2002	N/A	幼年特发性关节炎 anti-nucleus antibodies (ANA) \| B CD5+ lymphocytes \| T gamma/delta+ lymphocytes	37	Intra-articular Triamcinolone Hexacetonide	廠窪淵願襯鑰壓夢憲觸(淵艱蓋餘觸繭選窪糧構) = 鑰廠醖鏇鹽醖鬱遞醖網夢蓋願鑰鏇製鑰構顧鹽 (鏇廠遞衊醖網觸鑰鬱窪 ) 更多	积极	2002-06-12